Cholesterol Metabolism and Vascular Disease
Published Online: 15 SEP 2009
Copyright © 2001 John Wiley & Sons, Ltd. All rights reserved.
How to Cite
Olufadi, R., Wild, S. and Byrne, C. 2009. Cholesterol Metabolism and Vascular Disease. eLS. .
- Published Online: 15 SEP 2009
This is not the most recent version of the article. View current version (16 NOV 2015)
Cholesterol is packaged into lipoprotein particles in the liver and intestine and transported to peripheral tissues for normal cellular function. Reverse cholesterol transport is the mechanism by which excess cholesterol is transported back to the liver and is facilitated by high-density lipoproteins (HDLs). Increased plasma concentrations of cholesterol within the low-density lipoprotein (LDL) contribute to atherosclerotic vascular disease that commonly affects the coronary, cerebral and peripheral vascular circulation. Incontrovertible evidence now supports the use of the ‘statin’ class of drugs to decrease vascular disease. Statins inhibit hepatic cholesterol synthesis, increase hepatic low-density lipoprotein cholestrol (LDLc) receptor expression and consequently decrease plasma LDLc, to reduce risk of myocardial infarction in people at widely varying risk of heart disease. At present, there is limited evidence to support the use of drugs that modify high-density lipoprotein cholesterol (HDLc) to reduce risk of heart disease.
Endogenous and exogenous lipid pathways.
Low-density lipoprotein cholesterol (LDLc) and heart disease.
High-density lipoprotein (HDL) metabolism.
Modification of high-density lipoprotein cholesterol (HDLc) and heart disease.
Pathophysiology of vascular disease in relation to lipid metabolism.
- atherosclerotic vascular disease;
- randomized trials